A former hedge manager from Connecticut firm, SAC Capital, Mathew Martoma was last month jailed for 9 years for insider trading. Martoma gained inside information about clinical trials for an experimental Alzheimer's drug, bapineuzumab - being made by two drug firms Elan and Wyeth. When he found out the trials had not gone as well as hoped his firm, SAC Capital started selling off a $700 million position in the drug firms before the negative results were made public.
Recent stories from Nine To Noon
Get the RNZ app
for easy access to all your favourite programmes
